Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Prostaglandin analogue (topical IOP reduction)

Bimatoprost 0.03% Eye Drops (Lumigan)

Brand names: Lumigan

Bimatoprost 0.03% eye drops are a topical prostaglandin analogue (prostamide) used to reduce intraocular pressure in ocular hypertension and open-angle glaucoma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It lowers intraocular pressure by enhancing aqueous humour outflow, mainly via the uveoscleral route.

Prescribing in practice

  • Counsel that it can cause permanent iris darkening and darkening and increased growth of eyelashes and eyelid skin, with iris pigmentation change being irreversible.
  • Conjunctival hyperaemia is common, and it should be used cautiously where there is active intraocular inflammation or risk of macular oedema.
  • Blot excess solution from the skin to limit periocular pigmentation.

Monitoring

Monitor intraocular pressure to confirm efficacy and watch for pigmentary changes of the iris and periocular tissues, lash changes and conjunctival redness.

Counselling the patient

  • Expect possible changes to eye colour, lashes and eyelid skin, some of which may be permanent.
  • Use once at the recommended time of day and do not exceed the prescribed frequency, as more frequent use can reduce effectiveness.
  • Remove contact lenses before use and wait before reinserting.

Evidence & guidelines

Bimatoprost eye drops are an established prostaglandin analogue for glaucoma and ocular hypertension, a class recommended by NICE as first-line pressure-lowering therapy.

Reference: NICE CG85; EGS Glaucoma Guidelines 2020; Lumigan SPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways